BridgeMD
PAmidronate for Pain in Sternocostoclavicular hyperostosis: the PAPS-study, a double-blind randomized placebo-controlled trial
EU CTIS ID: 2023-510309-16-00
What this study is testing
To demonstrate that in CNO patients with pain 3-monthly treatment with pamidronate will result in a significant decrease in maximal pain score (as measured by Brief Pain Inventory (BPI) (10), compared to placebo.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- NRS score for maximal pain of ≥ 6/10 at lesion sites
- Signs of disease activity on imaging at lesion sites
- No treatment with bisphosphonates for the previous 6 months
You likely can't join if
- Age below 18 years of age
- Mental disability
- Active pregnancy wish, pregnancy or nursing
- Generalized pain without CNO related pain
- Bisphosphonate allergy
- Estimated glomerular filtration rate < 30 ml/min
See the full eligibility criteria
- NRS score for maximal pain of ≥ 6/10 at lesion sites
- Signs of disease activity on imaging at lesion sites
- No treatment with bisphosphonates for the previous 6 months
- Age below 18 years of age
- Mental disability
- Active pregnancy wish, pregnancy or nursing
- Generalized pain without CNO related pain
- Bisphosphonate allergy
- Estimated glomerular filtration rate < 30 ml/min
- Uncontrolled endocrine abnormalities
- Active cancer treatment
- Language barrier
- Severe co-morbidity, including poor mobility and other causes preventing attendance for control visits
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.